Oslo

• The REST (Replacing Steroids in the transplant ineligible) study. Ended recruitment
  2023-510194-34-00 4 2021-06-18 Multiple myeloma
• A Phase 3 study of Tafasitamab plus Lenalidomide in addition to Rituximab, versus Lenalidomide plus Rituximab in patients With Relapsed/Refr … Ended recruitment
  2023-504684-16-00 5 2021-06-05 follicular lymphoma (FL) and marginal zone lymphoma (MZL)
• Isatuximab in combination with belantamab mafodotin and dexamethasone in RRMM. Ended recruitment
  2024-514989-40-00 9 2021-05-17 Cancer
• An Open-label, Randomized Phase 3 Study of Immune and Targeted Combination Therapies, as First-line Treatment in Participants with Advanced … Ended recruitment
  2022-502122-41-00 5 2021-05-11 Clear cell renal cancer
• A research study to find out if the study treatment alpelisib (BYL719) is safe and can help others who have confirmed diagnosis of PIK3CA-re … Ended recruitment
  2023-508530-34-00 4 2021-04-19 PIK3CA-Related Overgrowth Spectrum (PROS)
• A Study of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome, or Non-Monoclonal Mast Cell Ac … Ended recruitment
  2024-514467-26-00 4 2021-04-07 Indolent Systemic Mastocytosis
• Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH) Ended recruitment
  2023-506962-30-00 5 2021-03-29 Non-alcoholic steatohepatitis (NASH)
• A study of patients with colorectal cancer that have a genetic abnormality in the BRAF gene taking encorafenib plus cetuximab with or withou … Ended recruitment
  2023-509405-77-00 5 2021-02-16 Colorectal cancer (BRAF V600E-mutant mCRC)
• An extension study to learn if Zilucoplan is safe and works over a long period in adult participants with generalized myasthenia gravis. Ended recruitment
  2024-512399-37-00 5 2020-12-29 Generalized Myasthenia Gravis
• A Phase 3 Trial of Epcoritamab vs Investigator’s Choice Chemotherapy in R/R DLBCL Ended recruitment
  2023-504830-23-00 5 2020-12-16 B-cell Lymphoma
• Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) Ended recruitment
  2023-504805-35-00 9 2020-10-22 Lymphoma of B-cell origin
• Ocrelizumab VErsus Rituximab off-Label at the Onset of Relapsing MS Disease (OVERLORD-MS) Ended recruitment
  2024-510716-71-00 5 2020-10-21 Multiple Sclerosis
• A Clinical trial to compare the combination of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone versus the combination of Carfilzomib-Lenal … Ended recruitment
  2024-513422-38-00 5 2020-09-28 Newly diagnosed multiple myeloma
• POLAR BEAR Ended recruitment
  2022-502887-19-00 5 2020-08-18 Diffuse Large B-Cell Lymphoma
• Isatuximab in combination with lenalidomide and dexamethasone in high-risk smoldering multiple myeloma Ended recruitment
  2023-507419-37-00 5 2020-06-25 Plasma cell myeloma
• A Study to Evaluate Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy Ended recruitment
  2024-518318-25-00 5 2020-06-24 Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell … Ended recruitment
  2023-503591-25-00 5 2020-06-09 Non-small cell lung cancer
• A multicenter trial assessing the impact of lipoprotein (a) lowering with pelacarsen (TQJ230) on major cardiovascular events in patients wit … Ended recruitment
  2023-508292-37-00 5 2020-03-06 Cardiovascular Disease
• Phase 3, Randomized, Double-Blind Study of Pembrolizumab versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiothera … Ended recruitment
  2022-501973-37-00 5 2020-01-30 Endometrial cancer
• Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with RRMM. Ended recruitment
  2023-509550-55-00 7 2020-01-21 Multiple Myeloma
• HOVON 156 AML: Treatment for acute myeloid leukemia (AML) or myelodysplastic syndrome with a FLT3 mutation with gilteritinib or midostaurin … Ended recruitment
  2022-502478-18-00 4 2019-12-20 Acute Myeloid Leukemia (AML)
• Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended recruitment
  2022-502604-67-00 10 2019-12-20 Malignant pleural mesothelioma (MPM)
• A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended recruitment
  2023-506551-23-00 5 2019-11-21 Recurrent or primary advanced (Stage III or IV) endometrial cancer
• Research study to comparison the effectivenes of combination of drugs called lenalidomide, carfilzomib, dexamethasone with combination of dr … Ended recruitment
  2024-518473-34-00 5 2019-11-20 Multiple Myeloma

Showing 361–384 of 508 trials